GlyProVac Overview

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

GlyProVac General Information

Description

Developer of a glycoprotein-based vaccine designed for the treatment of enterotoxigenic escherichia coli. The company's BEMAP technology allows comprehensive identification of any type of O-linked protein glycosylation that acts as a reservoir of attractive targets for antimicrobial intervention, enabling people to strengthen their immune systems thus preventing the infection caused by the enterotoxigenic escherichia coli bacterium.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rørhatten 4
  • 5220 Odense
  • Denmark
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Rørhatten 4
  • 5220 Odense
  • Denmark

GlyProVac Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlyProVac Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 03-Mar-2026 Completed Generating Revenue
10. Grant 01-Jan-2024 Completed Generating Revenue
9. Later Stage VC 28-Sep-2023 Completed Generating Revenue
8. Seed Round 30-Jun-2021 Completed Generating Revenue
7. Seed Round 07-Dec-2020 Completed Generating Revenue
6. Accelerator/Incubator Completed Generating Revenue
5. Angel (individual) 01-Jan-2018 Completed Generating Revenue
4. Grant Completed Generating Revenue
3. Grant $156K Completed Generating Revenue
2. Grant 01-Jan-2014 $368K Completed Generating Revenue
To view GlyProVac’s complete valuation and funding history, request access »

GlyProVac Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 3,742 $25.1 $25.1 1x $25.1 2.73%
Ordinary 18,655 $17.23 $17.23 1x $17.23 13.63%
To view GlyProVac’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GlyProVac Patents

GlyProVac Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025219177-A1 Optimized plasmids for expression of yghj polypeptides Pending 18-Apr-2024
AU-2023362022-A1 Glycosylated yghj polypeptides from uropathogenic e. coli Pending 19-Oct-2022
EP-4605414-A1 Glycosylated yghj polypeptides from uropathogenic e. coli Pending 19-Oct-2022
US-20260285915-A1 Glycosylated yghj polypeptides from uropathogenic e. coli Pending 19-Oct-2022
WO-2024083912-A1 Glycosylated yghj polypeptides from uropathogenic e. coli Inactive 19-Oct-2022 A61P31/04
To view GlyProVac’s complete patent history, request access »

GlyProVac Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GlyProVac Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
CARB-X University
Angel (individual) Minority
Angel (individual) Minority
Angel (individual) Minority
Syddansk Innovation Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

GlyProVac FAQs

  • Where is GlyProVac headquartered?

    GlyProVac is headquartered in Odense, Denmark.

  • What is the size of GlyProVac?

    GlyProVac has 4 total employees.

  • What industry is GlyProVac in?

    GlyProVac’s primary industry is Drug Discovery.

  • Is GlyProVac a private or public company?

    GlyProVac is a Private company.

  • What is GlyProVac’s current revenue?

    The current revenue for GlyProVac is .

  • How much funding has GlyProVac raised over time?

    GlyProVac has raised $2.15M.

  • Who are GlyProVac’s investors?

    CARB-X, , , , and Syddansk Innovation are 5 of 9 investors who have invested in GlyProVac.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process